News | October 08, 2010

Study Shows Bivalirudin Improves Survival in AMI

October 8, 2010 – New data from the HORIZONS-AMI trial shows that administering the anticoagulant bivalirudin (Angiomax) enhances survival in heart attack patients undergoing angioplasty after three years. The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium in Washington, D.C.

The study compared bivalirudin to the use of heparin plus a GP IIb/IIIa inhibitor. The data also showed that a drug-eluting stent (paclitaxel) was as safe and more effective than a bare-metal stent.

“The results at three years, representing the final report from the HORIZONS-AMI trial, are consistent with and extend the two-year data that we reported last year at TCT,” said Gregg W. Stone, M.D., professor of medicine at Columbia University College of Physicians and Surgeons, director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York Presbyterian Hospital/Columbia University Medical Center and co-director of the medical research and education division at the Cardiovascular Research Foundation. Stone is the principal investigator of the HORIZONS-AMI trial.

“The data demonstrate that use of bivalirudin alone, as opposed to a combination of heparin and a GP IIb/IIIa inhibitor, can save lives,” Stone said. “In addition, a significant reduction in second heart attacks has emerged over time in patients treated with bivalirudin.”

After three years, treatment with bivalirudin resulted in:

• A 36 percent reduction in major bleeding and a 24 percent reduction in re-infarction, with nonsignificantly different rates of stent thrombosis, target vessel revascularization (TVR) and stroke.

• A 44 percent reduction in cardiac mortality and a 25 percent reduction in all-cause mortality, the latter representing 18 lives saved per 1,000 patients treated with bivalirudin.

In addition, at three years, the implantation of a paclitaxel-eluting stent resulted in:

• A significant 40 percent reduction in ischemic target lesion revascularization (TLR), with preservation of the gains achieved within the first year over time.

• Nonsignificantly different rates of all-cause and cardiac mortality, re-infarction and stent thrombosis.

For more information: www.crf.org

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init